Vasomedical Inc (VASO) 0.3400 $VASO
Vasomedical Announces Cooperative Agreement with PSK for International Marketing of ECP Systems
PR Newswire - Wed Apr 16, 7:00AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of ECP therapy, today announced that it has entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. ("PSK" of Chongqing, China, a leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited ("VSK" , for the global marketing and sale of EECP and ECP therapy systems.
Vasomedical posts lesser net loss of USD1.1m and revenue growth of 12% in 2013
M2 - Fri Mar 28, 7:31AM CDT
Medical technology company Vasomedical (OTC BB:VASO) stated on Thursday its net loss of USD1.1m (USD0.01 per common share) for the year ended 31 December 2013.
Citigroup Shares Drop After Failing Fed Stress Test; Applied Genetic Technologies Announces IPO
ACCESSWIRE - Thu Mar 27, 11:38PM CDT
Citigroup Inc. (NYSE: C) - For an in-depth report on Citigroup Inc. follow: www.BullTrends.com/stockquote/C
Vasomedical Announces Financial Results for Fourth Quarter and Full Year for 2013
PR Newswire - Thu Mar 27, 8:15AM CDT
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO) today reported its operating results for the three months and year ended December 31, 2013.
Vasomedical to Report Fourth Quarter and Year End 2013 Results on March 27, 2014
PR Newswire - Fri Mar 21, 7:00AM CDT
Vasomedical, Inc. (OTC BB: VASO) announced today that it will release its financial results for the three months ended and year ended December 31, 2013 on Thursday, March 27, 2014.
Vasomedical Announces Biox's MobiCare(TM) Wireless Patient Monitors Receives Marketing Approval in China
PR Newswire - Mon Mar 17, 7:00AM CDT
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of ECP therapy, today announced that its wholly owned subsidiary Biox Instruments Co. Ltd., based in Wuxi, China, has received approval from the Chinese Food and Drug Administration (CFDA) to begin marketing its new MobiCare Wireless Patient Monitors in China.
Newfield Exploration Closes On Sale Of Its Malaysian Business
PR Newswire - Tue Feb 11, 7:00AM CST
Newfield Exploration Company (NYSE: NFX) today announces the closing of the previously announced sale of its business offshore Malaysia to SapuraKencana Petroleum Berhad, receiving total proceeds of approximately $898 million. The Share Purchase Agreement was originally executed with SapuraKencana on October 22, 2013, with an effective date of June 30, 2013. Proceeds from the sale will be used to reduce short-term borrowings under Newfield's credit facility and for general corporate purposes.
FDA Reclassifies ECP Devices for Refractory Angina as Class II
PR Newswire - Mon Jan 06, 3:25PM CST
Vasomedical, Inc. ("Vasomedical" (OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices including EECP® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that the U.S. Food and Drug Administration (FDA), Department of Health and Human Services, issued its final order on December 30, 2013, reclassifying external counter-pulsating (ECP) devices for treatment of chronic stable angina for patients that are refractory to anti-anginal medical therapy and without options for revascularization from class III to class II (special controls).
Vasomedical Recorded 33% Year-over-year Growth in Revenue for the Third Quarter of 2013
PR Newswire - Thu Nov 14, 7:00AM CST
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO) today reported its operating results for the three months ended September 30, 2013.
Vasomedical Again Named on Deloitte's Technology Fast 500 List
PR Newswire - Wed Nov 13, 7:45AM CST
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, today announced it has been named to the Deloitte's Technology Fast 500(TM) for the second consecutive year, with a ranking of 207 on the 2013 list, up from 443 on the 2012 list.
Vasomedical to Report Third Quarter 2013 Results on November 14, 2013
PR Newswire - Tue Nov 05, 7:00AM CST
Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended September 30, 2013 on Thursday, November 14, 2013.
Vasomedical to Showcase EECP® Therapy at 2013 Scientific Sessions of the American Heart Association
PR Newswire - Thu Oct 31, 7:30AM CDT
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the Company will attend the American Heart Association's 2013 Scientific Sessions from November 16 - 20, 2013 in Dallas, Texas to exhibit its EECP Therapy and BIOX(TM) ambulatory monitoring products.
EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
PR Newswire - Mon Sep 09, 7:30AM CDT
Vasomedical, Inc. ("Vasomedical" (OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that its EECP Therapy has been given a lla Class of Recommendation in the 2013 European Society of Cardiology (ESC) Guidelines on the Management of Stable Coronary Artery Disease (SCAD). The guidelines were released during ESC's annual meeting which took place from August 31 to September 3, 2013 in Amsterdam, the Netherlands.
OTC Daily Alert Stock Watch - Vasomedical, Inc. (OTCQB: VASO)
WorldStockWire - Fri Sep 06, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Vasomedical Announces Financial Results for the Second Quarter of 2013
PR Newswire - Tue Aug 13, 3:05PM CDT
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO) today reported its operating results for the three months ended June 30, 2013.
Vasomedical Inc is Featured as the Daily Momentum Gainer to watch on Smallcappower.com
Newsfile Corp - Fri Aug 09, 9:37AM CDT
full story)
Vasomedical to Report Second Quarter 2013 Results on August 13, 2013
PR Newswire - Tue Aug 06, 7:00AM CDT
Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended June 30, 2013 on Tuesday, August 13, 2013.
Vasomedical to Raise Awareness about EECP® Therapy as an Effective Treatment for Heart Disease in Diabetic Patients
PR Newswire - Mon Jun 03, 7:30AM CDT
The American Heart Association (AHA) Heart Disease and Stroke 2013 Statistical Update reported that 19.7 million Americans over the age of twenty have physician-diagnosed diabetes, and there are an additional eight million Americans with undiagnosed diabetes. The top causes of disability and death among patients with diabetes are heart disease and stroke, and these patients suffer more complications and higher failure rate with the current methods of treating heart disease, including medication, stenting and bypass surgery. It has been long established that Enhanced External Counterpulsation (EECP®) Therapy, a noninvasive treatment for patients with ischemic heart disease, is equally effective in treating heart disease for diabetic patients as it is in the non-diabetic patient population.
Vasomedical Announces Financial Results for the First Quarter of 2013
PR Newswire - Wed May 15, 3:15PM CDT
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO) today reported its operating results for the three months ended March 31, 2013.
Vasomedical to Report First Quarter 2013 Results on May 15, 2013
PR Newswire - Wed May 08, 8:00AM CDT
Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended March 31, 2013 on Wednesday, May 15, 2013.
Vasomedical Announces Cooperative Agreement with PSK for International Marketing of ECP Systems
PR Newswire - Wed Apr 16, 7:00AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of ECP therapy, today announced that it has entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. ("PSK" of Chongqing, China, a leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited ("VSK" , for the global marketing and sale of EECP and ECP therapy systems. Vasomedical posts lesser net loss of USD1.1m and revenue growth of 12% in 2013
M2 - Fri Mar 28, 7:31AM CDT
Medical technology company Vasomedical (OTC BB:VASO) stated on Thursday its net loss of USD1.1m (USD0.01 per common share) for the year ended 31 December 2013.
Citigroup Shares Drop After Failing Fed Stress Test; Applied Genetic Technologies Announces IPO
ACCESSWIRE - Thu Mar 27, 11:38PM CDT
Citigroup Inc. (NYSE: C) - For an in-depth report on Citigroup Inc. follow: www.BullTrends.com/stockquote/C
Vasomedical Announces Financial Results for Fourth Quarter and Full Year for 2013
PR Newswire - Thu Mar 27, 8:15AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO) today reported its operating results for the three months and year ended December 31, 2013. Vasomedical to Report Fourth Quarter and Year End 2013 Results on March 27, 2014
PR Newswire - Fri Mar 21, 7:00AM CDT
Vasomedical, Inc. (OTC BB: VASO) announced today that it will release its financial results for the three months ended and year ended December 31, 2013 on Thursday, March 27, 2014.
Vasomedical Announces Biox's MobiCare(TM) Wireless Patient Monitors Receives Marketing Approval in China
PR Newswire - Mon Mar 17, 7:00AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of ECP therapy, today announced that its wholly owned subsidiary Biox Instruments Co. Ltd., based in Wuxi, China, has received approval from the Chinese Food and Drug Administration (CFDA) to begin marketing its new MobiCare Wireless Patient Monitors in China. Newfield Exploration Closes On Sale Of Its Malaysian Business
PR Newswire - Tue Feb 11, 7:00AM CST
Newfield Exploration Company (NYSE: NFX) today announces the closing of the previously announced sale of its business offshore Malaysia to SapuraKencana Petroleum Berhad, receiving total proceeds of approximately $898 million. The Share Purchase Agreement was originally executed with SapuraKencana on October 22, 2013, with an effective date of June 30, 2013. Proceeds from the sale will be used to reduce short-term borrowings under Newfield's credit facility and for general corporate purposes.
FDA Reclassifies ECP Devices for Refractory Angina as Class II
PR Newswire - Mon Jan 06, 3:25PM CST
Vasomedical, Inc. ("Vasomedical"
(OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices including EECP® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that the U.S. Food and Drug Administration (FDA), Department of Health and Human Services, issued its final order on December 30, 2013, reclassifying external counter-pulsating (ECP) devices for treatment of chronic stable angina for patients that are refractory to anti-anginal medical therapy and without options for revascularization from class III to class II (special controls). Vasomedical Recorded 33% Year-over-year Growth in Revenue for the Third Quarter of 2013
PR Newswire - Thu Nov 14, 7:00AM CST
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO) today reported its operating results for the three months ended September 30, 2013. Vasomedical Again Named on Deloitte's Technology Fast 500 List
PR Newswire - Wed Nov 13, 7:45AM CST
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, today announced it has been named to the Deloitte's Technology Fast 500(TM) for the second consecutive year, with a ranking of 207 on the 2013 list, up from 443 on the 2012 list. Vasomedical to Report Third Quarter 2013 Results on November 14, 2013
PR Newswire - Tue Nov 05, 7:00AM CST
Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended September 30, 2013 on Thursday, November 14, 2013.
Vasomedical to Showcase EECP® Therapy at 2013 Scientific Sessions of the American Heart Association
PR Newswire - Thu Oct 31, 7:30AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the Company will attend the American Heart Association's 2013 Scientific Sessions from November 16 - 20, 2013 in Dallas, Texas to exhibit its EECP Therapy and BIOX(TM) ambulatory monitoring products. EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
PR Newswire - Mon Sep 09, 7:30AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that its EECP Therapy has been given a lla Class of Recommendation in the 2013 European Society of Cardiology (ESC) Guidelines on the Management of Stable Coronary Artery Disease (SCAD). The guidelines were released during ESC's annual meeting which took place from August 31 to September 3, 2013 in Amsterdam, the Netherlands. OTC Daily Alert Stock Watch - Vasomedical, Inc. (OTCQB: VASO)
WorldStockWire - Fri Sep 06, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Vasomedical Announces Financial Results for the Second Quarter of 2013
PR Newswire - Tue Aug 13, 3:05PM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO) today reported its operating results for the three months ended June 30, 2013. Vasomedical Inc is Featured as the Daily Momentum Gainer to watch on Smallcappower.com
Newsfile Corp - Fri Aug 09, 9:37AM CDT
full story)
Vasomedical to Report Second Quarter 2013 Results on August 13, 2013
PR Newswire - Tue Aug 06, 7:00AM CDT
Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended June 30, 2013 on Tuesday, August 13, 2013.
Vasomedical to Raise Awareness about EECP® Therapy as an Effective Treatment for Heart Disease in Diabetic Patients
PR Newswire - Mon Jun 03, 7:30AM CDT
The American Heart Association (AHA) Heart Disease and Stroke 2013 Statistical Update reported that 19.7 million Americans over the age of twenty have physician-diagnosed diabetes, and there are an additional eight million Americans with undiagnosed diabetes. The top causes of disability and death among patients with diabetes are heart disease and stroke, and these patients suffer more complications and higher failure rate with the current methods of treating heart disease, including medication, stenting and bypass surgery. It has been long established that Enhanced External Counterpulsation (EECP®) Therapy, a noninvasive treatment for patients with ischemic heart disease, is equally effective in treating heart disease for diabetic patients as it is in the non-diabetic patient population.
Vasomedical Announces Financial Results for the First Quarter of 2013
PR Newswire - Wed May 15, 3:15PM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO) today reported its operating results for the three months ended March 31, 2013. Vasomedical to Report First Quarter 2013 Results on May 15, 2013
PR Newswire - Wed May 08, 8:00AM CDT
Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended March 31, 2013 on Wednesday, May 15, 2013.
